Oral Solid Dosage CDMO Market Expansion Potential and Revenue Projection 2026 to 2035

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Oral Solid Dosage CDMO Market Size, Share & Trends Analysis Report By Service Type (Formulation Development, Process Development and Scale-Up, Clinical Trial Manufacturing (Phase I / II / III), Commercial Manufacturing, Packaging, Serialization, and Labelling, Analytical, Stability, and QC Services, Regulatory and CMC Support), By Dosage Form (Immediate-Release Tablets, Modified-Release Tablets (SR / CR / DR / ER / Pulsatile), Coated Tablets (Film, Sugar, Enteric), Hard Capsules (Gelatin and HPMC), Soft Gelatin Capsules, Orally Disintegrating Tablets (ODT), Multiparticulates (Pellets, Beads, Mini-Tablets, MUPS), Granules, Sachets, and Stick Packs, Powders for Oral Suspension, Chewables, Lozenges, and Effervescent Tablets),-Market Outlook And Industry Analysis 2035"

Oral Solid Dosage CDMO Market is estimated to grow at a 7.0% CAGR during the forecast period for 2026 to 2035.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com//request-sample/3648

Oral solid dosage (OSD) formulations are the backbone of pharmaceutical drug delivery. They include tablets, capsules, multiparticulates, powders, sachets, and other forms taken orally. Their ease of use, acceptance by patients, stability, cost-effective production, and ability to be made on a large scale make OSD products the preferred choice for many therapeutic agents. As pharmaceutical innovation progresses, creating complex oral formulations requires specialized knowledge in formulation. It also needs modern manufacturing methods, strong quality systems, and strict regulatory oversight during the product lifecycle.

The oral solid dosage (OSD) CDMO market has developed to meet changing manufacturing and development needs by offering specialized outsourcing services throughout the pharmaceutical product lifecycle. The market aids in formulation development, analytical testing, process scale-up, clinical supply manufacturing, commercial production, packaging, and regulatory services for pharmaceutical and biotechnology companies. Its customers range from large pharmaceutical companies to generic drug manufacturers, specialty pharma firms, and new biopharmaceutical companies. This variety shows how widely outsourced OSD services apply to both innovative and established drug portfolios. With demand coming from both developed and emerging pharmaceutical markets, CDMOs have become crucial partners in providing high-quality, scalable, and compliant manufacturing solutions worldwide.

The market is moving from traditional contract manufacturing to integrated development and manufacturing partnerships. Customers now look for complete solutions from early development to commercial supply. This change is widening the role of OSD CDMOs beyond just manufacturing to include strategic lifecycle management, technology transfer, and supply chain optimization. As pharmaceutical companies focus on operational flexibility, manufacturing strength, and access to modern production technologies, the OSD CDMO market is turning into a key growth platform that encourages innovation, commercialization, and the long-term improvement of pharmaceutical manufacturing.

List of Prominent Players in the Oral Solid Dosage CDMO Market:
• Catalent, Inc. (Novo Holdings)
• Lonza Group AG (Capsugel Division)
• Thermo Fisher Scientific / Patheon Pharma Services
• Recipharm AB
• Piramal Pharma Solutions
• Boehringer Ingelheim BioXcellence
• Aenova Group
• Siegfried Holding AG
• CordenPharma International
• Hovione
• Almac Group
• Rottendorf Pharma
• Delpharm
• Famar Group
• Quotient Sciences
• Sterling Pharma Solutions
• Adare Pharma Solutions
• PCI Pharma Services
• Cambrex Corporation
• Alcami Corporation
• UPM Pharmaceuticals
• Pharmaceutics International, Inc.
• AbbVie Contract Manufacturing
• Bora Pharmaceuticals (Taiwan)
• Jubilant Pharmova Limited
• Granules India Limited
• WuXi STA (a WuXi AppTec company)
• Samsung Biologics (OSD Entry)
• Dr. Reddy's Contract Pharmaceutical Services (CPS)

Add our site to Google Preferred Sources for quality content: https://google.com/preferences/source?q=insightaceanalytic.com

Market Dynamics:
Drivers:
The increasing demand for oral solid dosage (OSD) drugs is a major factor in the OSD CDMO market. Tablets, capsules, and other oral formulations are the most commonly prescribed and preferred forms because they are easy to take, stable, cost-effective, and convenient for patients. The rising number of chronic diseases, higher use of generic and specialty medicines, and a growing pipeline of small-molecule therapeutics are boosting production volumes. This trend pushes pharmaceutical companies to outsource OSD development and manufacturing to specialized CDMOs that have scalable production capabilities and strong formulation knowledge.

Challenges:
The oral solid dosage (OSD) CDMO market faces several operational challenges. These include strict regulatory compliance, pricing pressure, complex technology transfer, and supply chain disruptions. CDMOs must keep investing in quality systems, process validation, and GMP compliance. They also need to maintain consistent product quality across various customer projects. Intense competition in the generic pharmaceutical sector limits pricing flexibility. This makes it hard to balance cost efficiency with investments in better manufacturing capabilities. Furthermore, scaling up formulations from development to commercial production demands precise process optimization. Disruptions in the supply of APIs, excipients, and packaging materials can further affect production schedules, raise costs, and reduce overall manufacturing efficiency.

Regional Trends:
North America leads the oral solid dosage (OSD) CDMO market because it has a strong pharmaceutical manufacturing system. The region has many global pharmaceutical and biotechnology companies, along with a concentration of top CDMOs that provide complete development and manufacturing services. It benefits from solid manufacturing infrastructure, widespread outsourcing, and deep expertise in formulation development, clinical manufacturing, and large-scale production.

Moreover, ongoing investments in manufacturing capacity, new technologies like continuous manufacturing and digitalization, and a strong pipeline of small-molecule drugs further enhance the region's position. High regulatory standards and a strong focus on quality and innovation make North America the preferred site for outsourced OSD development and manufacturing services.

Customize this Study according to your Requirements @ https://www.insightaceanalytic.com/customization/3648

Key Development
• May 2026: CordenPharma acquired AmbioPharm, a U.S.-based peptide CDMO, to expand its peptide API development and manufacturing capabilities. The acquisition strengthened its global CDMO network by increasing manufacturing capacity in the U.S. and China and enhancing support for complex peptide programs and global supply.

Segmentation of Oral Solid Dosage CDMO Market-
By Service Type -
• Formulation Development
• Process Development and Scale-Up
• Clinical Trial Manufacturing (Phase I / II / III)
• Commercial Manufacturing
• Packaging, Serialization, and Labelling
• Analytical, Stability, and QC Services
• Regulatory and CMC Support
By Dosage Form -
• Immediate-Release Tablets
• Modified-Release Tablets (SR / CR / DR / ER / Pulsatile)
• Coated Tablets (Film, Sugar, Enteric)
• Hard Capsules (Gelatin and HPMC)
• Soft Gelatin Capsules
• Orally Disintegrating Tablets (ODT)
• Multiparticulates (Pellets, Beads, Mini-Tablets, MUPS)
• Granules, Sachets, and Stick Packs
• Powders for Oral Suspension
• Chewables, Lozenges, and Effervescent Tablets
By Manufacturing Technology -
• Wet Granulation
• Dry Granulation and Roller Compaction
• Direct Compression
• Hot Melt Extrusion
• Spray Drying
• Fluid Bed Processing and Coating
• Compression and Film Coating
• Encapsulation (Powder, Pellet, LFHC)
• Continuous Manufacturing
• 3D Printing
By API Potency / Containment Class -
• Non-Potent / Standard (OEB 1-3)
• Potent (OEB 4)
• Highly Potent / HPAPI (OEB 5)
• Cytotoxic and Hormonal
By Therapeutic Area -
• Oncology
• Cardiovascular and Metabolic (including Oral GLP-1, Statins, Anti-Hypertensives)
• Central Nervous System (including Abuse-Deterrent Formulations)
• Anti-Infectives
• Respiratory
• Gastrointestinal
• Pain Management
• Other Therapeutic Areas
By Customer Type -
• Big Pharma (Top 20)
• Mid-Cap Pharma
• Specialty and Branded-Generic Pharma
• Emerging Biotech and Virtual Companies
• Generic Manufacturers
By Contract Structure -
• Fee-for-Service
• FTE-Based
• Milestone / Risk-Sharing
• Royalty and Profit-Sharing
By Development Phase -
• Pre-Clinical / Discovery Support
• Clinical Phase I
• Clinical Phase II
• Clinical Phase III
• Commercial Manufacturing
• Post-Approval Lifecycle Management
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Read Comprehensive Report Overview: https://www.insightaceanalytic.com/report/oral-solid-dosage-cdmo-market/3648

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: https://www.insightaceanalytic.com/
Tel : +1 607 400-7072
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.